This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundPatients with severe mitral regurgitation and cardiogenic shock demonstrate a poor prognosis. The primary outcome was device success and allcause death, while secondary outcomes included myocardial infarction, stroke, and heart failure hospitalization rates at 30day and intermediateterm followup.
Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Kodali, MD, pictured here, is one of the members of its leadership team, and director of the Structural Heart and Valve Center at CUIMC/NewYork-Presbyterian Hospital.
milla1cf Mon, 06/03/2024 - 12:36 June 3, 2024 — HighLife SAS , a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe Mitral Regurgitation (MR), announced today that the U.S. I am honored to lead the HighLife pivotal study.
BACKGROUND:Transcatheter edge-to-edge mitral valve (MV) repair (TEER) is an effective treatment for patients with primary mitral regurgitation at prohibitive risk for surgical MV repair (MVr). Circulation: Cardiovascular Interventions, Ahead of Print.
The cardiothoracic surgery programs at four Northwell Health hospitals received this distinguished accolade, showcasing their commitment to delivering exceptional care and achieving outstanding outcomes. of participants nationally scored in this category.
Totally endoscopic robotic mitral valve repair is the least invasive surgical therapy for mitral valve disease. Robotic mitral valve surgery demonstrates faster recovery with shorter hospital stays, less morbidity, and equivalent mortality and mid-term durability compared to sternotomy.
milla1cf Mon, 12/18/2023 - 15:43 December 18, 2023 — The Department of Cardiovascular Surgery at The Mount Sinai Hospital has received the highest possible three-star recognition in all of the cardiac surgery categories in the 2020-2023 Society of Thoracic Surgeons (STS) report. The Mount Sinai Hospital is also No.
In patients with failed mitral valve prostheses, what are the clinical outcomes of redo surgical mitral valve replacement (SMVR) versus transcatheter mitral valve replacement (TMVR), and how does hospital case volume relate to outcomes?
Two studies analyzing data from the STS/ACC TVT Registry exploring out-of-hospital 30-day mortality after mitral transcatheter edge-to-edge repair (TEER) and one-year cause-specific mortality after TAVR were published in JACC: Cardiovascular Interventions on March 19.
RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.
Procedural, in-hospital, and follow-up clinical outcomes were evaluated after procedures.ResultsThe average age of the 130 patients was 71.24.4 All patients were pre-TAVR assessed by transthoracic echocardiography and computed tomography of the aortic valve (AV) and relevant left cardiac and vascular anatomy. years old, 55.4%
Background The clinical prognosis of mitral valve surgery at morning, afternoon, and evening is not yet clear. The aim of the study is to investigate the impact of different time periods of surgery in the morning, afternoon and evening on the short-term and long-term results of mitral valve surgery.
Heart team processes, mandatory attendees and investigations vary significantly between hospitals. We assessed outcomes following mitral valvular surgery in a tertiary referral centre with a dedicated mitral multi-disciplinary team (MDT). Between 2016 and 2020, 395 patients with mitral valvular disease were discussed at MDT.
BACKGROUND:Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. Poverall=NS) were nonsignificant, and the incidence of overall in-hospital complications was comparable among groups. In the matched population, differences in mortality (30 days: 4.2% 2.44];P=0.035).
These key takeaways from the research letter on IVL-facilitated valvuloplasty for severely calcified mitral valve stenosis are published in the Journal of the American College of Cardiology (JACC) Cardiovascular Interventions. We are looking forward to treating patients who have no other options for mitral stenosis diseased valves.”
It is one of only two New Jersey hospitals offering the trial to patients. Many patients with symptoms of mitral regurgitation are not candidates for open heart surgery due to their advanced age or competing comorbidities, nor are they candidates for the only alternative, the MitraClip device.
The academic medical centers received three-star ratings in isolated coronary artery bypass grafting (CABG) and isolated mitral valve replacement and repair (MVRR) surgeries. The Society of Thoracic Surgeons’ three star ratings are among the most prestigious quality indicators for hospitals providing open heart surgery,” said Elizabeth A.
Percutaneous balloon mitral valvotomy (PBMV) is a good and preferred therapy choice over surgical commissurotomy for patients with rheumatic mitral stenosis (MS). Conversely, AF leads to a lower PBMV success rate as well as worse long-term and in-hospital outcomes.
Nature Reviews Cardiology, Published online: 19 September 2024; doi:10.1038/s41569-024-01089-9 In patients with heart failure and secondary mitral valve regurgitation, transcatheter edge-to-edge repair is non-inferior to mitral valve surgery with respect to a composite of death, hospitalization for heart failure, reintervention, implantation of an (..)
Video Transcatheter-Based Mitral Valve Repair and Replacement nboden Tue, 07/17/2018 - 12:56 The latest advances in mitral valve repair and replacement include a shift toward the transseptal platform. Sloan Guy, MD, MBA – Weill Cornell/New York Presbyterian Hospital Stephen F.
based Duke Health has performed the world's first living mitral valve replacement after a heart transplant patient donated healthy valves from their original heart to two other patients. A team from Durham, N.C.-based
Mitral transcatheter edge-to-edge repair (M-TEER) reduced cardiovascular death and heart failure (HF)-related hospitalizations with improved health status in patients with HF and moderate to severe functional mitral regurgitation (FMR), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Kodali, MD, pictured here, is one of the members of its leadership team, and director of the Structural Heart and Valve Center at CUIMC/NewYork-Presbyterian Hospital.
AimOne of the philosophies of minimally invasive mitral surgery is to enhance recovery after surgery (ERAS). In this report, we aim to present institutional protocol for ERAS and its results in patients who underwent totally endoscopic mitral valve surgery (TEMVS).Patients Mitral repair was performed in 58.4% of the cases.
On the contrary, the use of transcatheter edge-to-edge mitral valve repair (TEER) has exponentially increased over the past decade, expanding its potential use even in patients on the heart transplantation waiting list.
Goar received the recognition during a special ceremony in Paris, France, along with esteemed cardiothoracic surgeon, Professor Ottavio Alfieri of San Raffaele Hospital in Milan, Italy. The Ethica Award is presented every year to outstanding colleagues for their achievements and contributions to the cardiovascular field.
BackgroundTranscatheter edgetoedge repair of the mitral valve (mTEER) reduced a hierarchical end point that included death and heart failure hospitalization in COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation Trial).
Mitral valve failure is one of the most common valvular heart diseases worldwide. Valve replacement and repair have an impact on the quality of life of patients. Therefore, the present study was conducted to c.
BACKGROUND:Limited data exist regarding the impact of mitral annular calcification (MAC) on outcomes of transcatheter edge-to-edge repair for mitral regurgitation (MR).METHODS:We Circulation: Cardiovascular Interventions, Ahead of Print. with functional MR) who underwent an isolated, first-time intervention. versus 9.6%;P=0.016;
milla1cf Mon, 01/08/2024 - 14:35 January 8, 2024 — University Hospitals (UH) Harrington Heart & Vascular Institute recently became the first center in the world to implant Medtronic’s Penditure Left Atrial Appendage (LAA) Exclusion System through a minimally invasive approach during a mitral valve repair procedure.
BackgroundMitral regurgitation (MR) is the most common valvular disease in the United States and increases the risk of death and hospitalization. During the study period, 26 076 inpatients had a diagnosis of MR. Compared with patients without MR, these patients had more comorbidities and higher inpatient mortality.
The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first transcatheter aortic valve replacement (TAVR) in 2002, as well as the first transcatheter mitral commissurotomy in 1995 and the first balloon aortic valvuloplasty in 1986. He passed away Feb. 16, 2024 at the age of 79.
will provide up-to-date insights on the management of patients with Barlow’s disease with mitral valve prolapse and annular disjunction. The discussion will be based on a real patient undergoing mitral valve repair and having long-term follow-up for that condition. The case will be presented by an early career surgeon. 2:30 p.m.
High grade atrioventricular block requiring pacemaker (PPM) implantation is a common complication of mitral valve replacement (MVR) and is associated with longer hospital stays and higher readmission rates. These clinical outcomes have not been examined in large nationally representative cohorts.
As is shown in the study of 224 hearts with so-called mitral annular disjunction, 1 the wheel has now come full circle. 2 The investigators working at Johns Hopkins Hospital had noticed the anatomical arrangement in their investigation of over 900 hearts coming to autopsy, and being examined using a standardised technique.
The International Registry of MitraClip in Acute Mitral Regurgitation following Acute Myocardial Infarction (IREMMI). Methods and results The International Registry of MitraClip in Acute Mitral Regurgitation following Acute Myocardial Infarction (IREMMI) includes 187 patients with severe MR post-MI managed with TEER.
Is there a relationship between site-level volumes and outcomes for transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER)?
BACKGROUND:This study aimed to compare the incidence and prognostic implications of new-onset conduction disturbances after surgical aortic valve replacement (SAVR) in patients with bicuspid aortic valve (BAV) aortic stenosis (AS) versus patients with tricuspid aortic valve (TAV) AS (ie, BAV-AS and TAV-AS, respectively).
Severe mitral regurgitation (MR) also causes a low-flow state, adding complexity to diagnosis and management. BACKGROUND:Patients with paradoxical low-flow, low-gradient severe aortic stenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction.
While hospitals continue to enroll patients as part of ASCENT ASD in several countries, we are excited that these positive outcomes showcase the potential for reSept to soon be the new standard of care,” said Laurent Grandidier, atHeart Medical CEO. Around 100 patients have been implanted with reSept to date.
BackgroundPrior studies investigating the impact of residual mitral regurgitation (MR), tricuspid regurgitation (TR), and elevated predischarge transmitral mean pressure gradient (TMPG) on outcomes after mitral transcatheter edge‐to‐edge repair (TEER) have assessed each parameter in isolation. Overall, mean age was 76.7±10.6
We know that structural heart disease and heart failure are the leading causes of hospitalization and morbidity in the U.S. Standalone performance for significant major valve disease pathology (aortic stenosis and regurgitation and mitral and tricuspid regurgitation) had a 93 percent sensitivity and 93 percent specificity.
“Edwards has a long history of leading innovation and pioneering new therapies to address the unmet needs of patients with structural heart disease,” said Daveen Chopra , Edwards’ corporate vice president, transcatheter mitral and tricuspid therapies. “We
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
45 
Let's personalize your content